Form 20F & earnings guidance

GlaxoSmithKline PLC
08 March 2005

Issued - 7.00am Tuesday, 8th March 2005, London - LSE Announcement



         PUBLICATION OF GSK'S FORM 20-F AND REVIEW OF EARNINGS GUIDANCE

Today, 8th March 2005, GSK is filing its Annual Report on Form 20-F for 2004
with the Securities and Exchange Commission, and this will include updated
references to the US Food and Drug Administration's (FDA) actions to halt
distribution of supplies of Paxil CR and Avandamet due to manufacturing issues
at the Group's Cidra, Puerto Rico facility.

The Company is working with the FDA to resolve the manufacturing issues with
these products as quickly as possible, although the timing of this and the
financial impact on the Company's earnings are currently uncertain.

Subject to this uncertainty, GSK's published earnings guidance for 2005 remains
EPS percentage growth in the low double-digit range (at constant exchange rates)
on an International Financial Reporting Standards basis.



S M Bicknell,
Company Secretary

8th March 2005

                                  ***********

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.  For Company
information visit www.gsk.com.



Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform
Act of 1995, the Company cautions investors that any forward-looking statements
or projections made by the Company, including those made in this Announcement,
are subject to risks and uncertainties that may cause actual results to differ
materially from those projected.  Factors that may affect the Group's operations
are described under 'Risk Factors' in the Operating and Financial Review and
Prospects in the Company's Annual Report on Form 20-F for 2004 which will be
filed with the Securities and Exchange Commission today.


Enquiries:


UK Media enquiries:
                                     Philip Thomson        [phone]
                                     David Mawdsley        [phone]
                                     Chris Hunter-Ward     [phone]

US Media enquiries:                  Nancy Pekarek         [phone]
                                     Mary Anne Rhyne       [phone]
                                     Patricia Seif         (215)  751 7709

European Analyst/Investor enquiries: Duncan Learmouth      [phone]
                                     Anita Kidgell         [phone]

US Analyst/ Investor enquiries:      Frank Murdolo         [phone]
                                     Tom Curry             [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange